Otsuka (OTCMKTS:OTSKY) Announces Earnings Results

Otsuka (OTCMKTS:OTSKY) announced its quarterly earnings results on Tuesday. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16, Zacks reports. The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.80 billion. Otsuka had a return on equity of 12.52% and a net margin of 14.76%. Otsuka updated its FY 2026 guidance to 1.610-1.610 EPS.

Otsuka Stock Performance

Shares of OTSKY stock opened at $35.48 on Wednesday. The stock has a market capitalization of $38.11 billion and a PE ratio of 15.43. Otsuka has a 52-week low of $21.64 and a 52-week high of $36.55. The stock’s 50-day moving average price is $33.90 and its 200 day moving average price is $30.56. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05.

Analyst Ratings Changes

A number of analysts have recently commented on the company. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. Morgan Stanley upgraded Otsuka to an “overweight” rating in a research report on Friday, January 23rd. UBS Group upgraded Otsuka to a “hold” rating in a research report on Tuesday, January 27th. Finally, Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.